Genentech Phase III CELESTIMO shows Lunsumio regimen improves PFS
Genentech said its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met the primary endpoint with statistically significant, clinically meaningful PFS improvement versus Rituxan plus lenalidomide in relapsed/refractory follicular lymphoma; OS data are immature and safety showed no new signals.
Genentech said the Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint, with a statistically significant and clinically meaningful improvement in PFS versus Rituxan plus lenalidomide in relapsed/refractory FL. Overall survival data were immature, and safety showed no new signals.